*August 2021* Attention All Resisters! A new clinical trial finder, Medifind, is now live, which may help EGFR Resisters to quickly narrow down

*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor

*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated

This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered